Health and Wellness Clinical Group
1501 Edgemore Avenue · Salisbury, MD 21801
All Shore Infusion and Wellness Center · 1305 South Division Street · Salisbury, MD 21804
4.9· 33 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
All Shore Infusion and Wellness Center is an IV therapy and wellness practice in Salisbury, Maryland. Its website describes IV infusions of vitamins, fluids and nutrients, including blends aimed at recovery and rehydration, and says it brings more than 26 years of industry experience; it introduces Beth Laramore, CRNP-FNP, who began her medical career in the U.S. Air Force in 1989. On Google it has a 4.9-star rating across 33 reviews dating to 2022, 3 in the past year, with reviewers most often mentioning the staff, the team's knowledge and scheduling.
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Counts computed by RetaMaps from public Google reviews; most recent review 2026-07-29. Read the reviews themselves on the practice's Google listing.
Rated ★4.9 across 33 Google reviews. Of the 30 reviews we analyzed, 29 (97%) are positive (4–5★) and 1 (3%) are negative (1–2★).
Very few complaints — only 1 negative review, with no recurring theme.
Anna C.★★★★★2026-07-29I was very excited for my appointment here. The reviews are awesome. But I have sat waiting at the front door twice with no one showing up. Both times I received a confirmation email. Don't think I'll try a third.
Nina E.★★★★★2026-02-05Super easy experience. Very professional, knowledgeable, and efficient. Couldn’t be happier and I’m finally hydrated!
Meghan F.★★★★★2025-11-25Beth is amazing and the IVs are life changing. She offers a wide variety of options for hydration, vitamins, etc. It’s a cozy location which makes the experience that much more enjoyable. Highly recommend!
Sean S.★★★★★2025-06-17Wife has anemia and the IV infusion helped so much. The place is clean and has a good vibe
Kay S.★★★★★2025-06-17Absolutely recommend, not only did she make me feel super comfortable she explained everything perfectly she was so sweet and just a great vibe to be around , I'm so greatful I found her business! If your questioning weather it's something you should do as a mother of five kids this is a lifesaver ! Got me in literally the next day of scheduling! 10/10
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
1501 Edgemore Avenue · Salisbury, MD 21801
1344 South Division Street · Salisbury, MD 21804
5.0(219 Google reviews · 38 in past year)
113 West Main Street · Salisbury, MD 21801
4.8(36 Google reviews · 23 in past year)
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs